Article: The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes - Is it Advantageous?

Safe and effective therapies for type 2 diabetes are needed to reduce the burden of late complications and costs associated with this chronic disease. Hypoglycaemia and body weight gain are side effects and limitations of the therapy with insulin and/or sulphonylureas. Recently, the combination of glucagon-like peptide-1 (GLP-1) receptor agonists and insulin has become available, which is associated with good efficacy and less risk for hypoglycaemia and weight gain. This editorial discusses the strategies to escalate treatment in type 2 diabetes in view of this novel combination and discusses its placement within the therapeutic algorithm of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Recent developments to simplify this combination therapy are also dealt with.

Citing Articles

RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020.

Chawla R, Madhu S, Makkar B, Ghosh S, Saboo B, Kalra S Indian J Endocrinol Metab. 2020; 24(1):1-122.

PMID: 32699774 PMC: 7328526. DOI: 10.4103/ijem.IJEM_225_20.

Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement.

Giorgino F, Penfornis A, Pechtner V, Gentilella R, Corcos A Patient Prefer Adherence. 2018; 12:707-719.

PMID: 29765207 PMC: 5944456. DOI: 10.2147/PPA.S151736.

Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.

Valentine V, Goldman J, Shubrook J Diabetes Ther. 2017; 8(4):739-752.

PMID: 28721686 PMC: 5544623. DOI: 10.1007/s13300-017-0287-y.

References

1.

Diamant M, Nauck M, Shaginian R, Malone J, Cleall S, Reaney M . Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care. 2014; 37(10):2763-73. DOI: 10.2337/dc14-0876. View

2.

Levin P, Wei W, Wang L, Pan C, Douglas D, Baser O . Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes. Curr Med Res Opin. 2012; 28(3):439-46. DOI: 10.1185/03007995.2012.654850. View

3.

Buse J, Bergenstal R, Glass L, Heilmann C, Lewis M, Kwan A . Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2010; 154(2):103-12. DOI: 10.7326/0003-4819-154-2-201101180-00300. View

4.

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012; 55(6):1577-96. DOI: 10.1007/s00125-012-2534-0. View

5.

Seino Y, Min K, Niemoeller E, Takami A . Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012; 14(10):910-7. PMC: 3466411. DOI: 10.1111/j.1463-1326.2012.01618.x. View

6.

Rosenstock J, Rodbard H, Bain S, DAlessio D, Seufert J, Thomsen A . One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. J Diabetes Complications. 2013; 27(5):492-500. DOI: 10.1016/j.jdiacomp.2013.04.008. View

7.

Meier J . GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012; 8(12):728-42. DOI: 10.1038/nrendo.2012.140. View

8.

Nauck M . Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011; 124(1 Suppl):S3-18. DOI: 10.1016/j.amjmed.2010.11.002. View

9.

Nauck M, Meier J . Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?. Nat Rev Endocrinol. 2011; 7(4):193-5. DOI: 10.1038/nrendo.2011.30. View

10.

DeVries J, Bain S, Rodbard H, Seufert J, DAlessio D, Thomsen A . Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care. 2012; 35(7):1446-54. PMC: 3379583. DOI: 10.2337/dc11-1928. View

11.

Holst J, Vilsboll T . Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes Obes Metab. 2012; 15(1):3-14. DOI: 10.1111/j.1463-1326.2012.01628.x. View

The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes - Is It Advantageous?